← All trials

NCT07299695

Phase 3Interventional

Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.

View on ClinicalTrials.gov ↗

Timeline

Start date
Dec 31, 2025
Primary completion
Jun 30, 2028
Completion date
Dec 31, 2028
First posted
Dec 23, 2025
Last posted
Dec 23, 2025
Enrollment
196
Arms / groups
2 / —
Source
AACT · ctgov ingestion

Sponsors

Drugs studied

CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.